TY - JOUR
T1 - Effects of olmesartan-based treatment on masked, white-coat, poorly controlled, and well-controlled hypertension
T2 - HONEST study
AU - Kario, Kazuomi
AU - Saito, Ikuo
AU - Kushiro, Toshio
AU - Teramukai, Satoshi
AU - Ishikawa, Yusuke
AU - Kobayashi, Fumiaki
AU - Shimada, Kazuyuki
PY - 2014/6
Y1 - 2014/6
N2 - The authors examined the effects of olmesartan-based treatment on clinic systolic blood pressure (CSBP) and morning home systolic blood pressure (HSBP) in 21,340 patients with masked hypertension (MH), white-coat hypertension (WCH), poorly controlled hypertension (PCH), and well-controlled hypertension (CH) using data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) study. MH, WCH, PCH, and CH were defined using CSBP 140 mm Hg and MHSBP 135 mm Hg as cutoff values at baseline. At 16 weeks, the MH, WCH, PCH, and CH groups had changes in CSBP by -1.0, -15.2, -23.1, and 1.8 mm Hg, and changes in morning HSBP by -12.5, 1.0, -20.3, and 2.0 mm Hg, respectively. In conclusion, in "real-world" clinical practice, olmesartan-based treatment decreased high morning HBP or CBP without excessive decreases in normal morning HBP or CBP according to patients' BP status.
AB - The authors examined the effects of olmesartan-based treatment on clinic systolic blood pressure (CSBP) and morning home systolic blood pressure (HSBP) in 21,340 patients with masked hypertension (MH), white-coat hypertension (WCH), poorly controlled hypertension (PCH), and well-controlled hypertension (CH) using data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) study. MH, WCH, PCH, and CH were defined using CSBP 140 mm Hg and MHSBP 135 mm Hg as cutoff values at baseline. At 16 weeks, the MH, WCH, PCH, and CH groups had changes in CSBP by -1.0, -15.2, -23.1, and 1.8 mm Hg, and changes in morning HSBP by -12.5, 1.0, -20.3, and 2.0 mm Hg, respectively. In conclusion, in "real-world" clinical practice, olmesartan-based treatment decreased high morning HBP or CBP without excessive decreases in normal morning HBP or CBP according to patients' BP status.
UR - http://www.scopus.com/inward/record.url?scp=84902376096&partnerID=8YFLogxK
U2 - 10.1111/jch.12323
DO - 10.1111/jch.12323
M3 - Article
C2 - 24766515
AN - SCOPUS:84902376096
SN - 1524-6175
VL - 16
SP - 442
EP - 450
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 6
ER -